Search Results - "Brown, Jennifer R"

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia by Landau, Dan A., Carter, Scott L., Stojanov, Petar, McKenna, Aaron, Stevenson, Kristen, Lawrence, Michael S., Sougnez, Carrie, Stewart, Chip, Sivachenko, Andrey, Wang, Lili, Wan, Youzhong, Zhang, Wandi, Shukla, Sachet A., Vartanov, Alexander, Fernandes, Stacey M., Saksena, Gordon, Cibulskis, Kristian, Tesar, Bethany, Gabriel, Stacey, Hacohen, Nir, Meyerson, Matthew, Lander, Eric S., Neuberg, Donna, Brown, Jennifer R., Getz, Gad, Wu, Catherine J.

“…Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by…”
Get full text

Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients" by Brown, Jennifer R

Get full text

Targeting Bruton’s Tyrosine Kinase in CLL by Ahn, Inhye E., Brown, Jennifer R.

“…Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other…”
Get full text

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer by Glaviano, Antonino, Foo, Aaron S C, Lam, Hiu Y, Yap, Kenneth C H, Jacot, William, Jones, Robert H, Eng, Huiyan, Nair, Madhumathy G, Makvandi, Pooyan, Geoerger, Birgit, Kulke, Matthew H, Baird, Richard D, Prabhu, Jyothi S, Carbone, Daniela, Pecoraro, Camilla, Teh, Daniel B L, Sethi, Gautam, Cavalieri, Vincenzo, Lin, Kevin H, Javidi-Sharifi, Nathalie R, Toska, Eneda, Davids, Matthew S, Brown, Jennifer R, Diana, Patrizia, Stebbing, Justin, Fruman, David A, Kumar, Alan P

“…The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and…”
Get full text

Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia by Landau, Dan A., Clement, Kendell, Ziller, Michael J., Boyle, Patrick, Fan, Jean, Gu, Hongcang, Stevenson, Kristen, Sougnez, Carrie, Wang, Lili, Li, Shuqiang, Kotliar, Dylan, Zhang, Wandi, Ghandi, Mahmoud, Garraway, Levi, Fernandes, Stacey M., Livak, Kenneth J., Gabriel, Stacey, Gnirke, Andreas, Lander, Eric S., Brown, Jennifer R., Neuberg, Donna, Kharchenko, Peter V., Hacohen, Nir, Getz, Gad, Meissner, Alexander, Wu, Catherine J.

“…Intratumoral heterogeneity plays a critical role in tumor evolution. To define the contribution of DNA methylation to heterogeneity within tumors, we performed…”
Get full text

PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here? by Skånland, Sigrid S, Brown, Jennifer R

“…Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia (CLL). However, the severe toxicity profile associated with the…”
Get full text

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia by Byrd, John C, Harrington, Bonnie, O’Brien, Susan, Jones, Jeffrey A, Schuh, Anna, Devereux, Steve, Chaves, Jorge, Wierda, William G, Awan, Farrukh T, Brown, Jennifer R, Hillmen, Peter, Stephens, Deborah M, Ghia, Paolo, Barrientos, Jacqueline C, Pagel, John M, Woyach, Jennifer, Johnson, Dave, Huang, Jane, Wang, Xiaolin, Kaptein, Allard, Lannutti, Brian J, Covey, Todd, Fardis, Maria, McGreivy, Jesse, Hamdy, Ahmed, Rothbaum, Wayne, Izumi, Raquel, Diacovo, Thomas G, Johnson, Amy J, Furman, Richard R

“…Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had…”
Get full text

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab by Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.

“…Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase…”
Get full text

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity by Lampson, Benjamin L., Kasar, Siddha N., Matos, Tiago R., Morgan, Elizabeth A., Rassenti, Laura, Davids, Matthew S., Fisher, David C., Freedman, Arnold S., Jacobson, Caron A., Armand, Philippe, Abramson, Jeremy S., Arnason, Jon E., Kipps, Thomas J., Fein, Joshua, Fernandes, Stacey, Hanna, John, Ritz, Jerome, Kim, Haesook T., Brown, Jennifer R.

“…Idelalisib is a small-molecule inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). To…”
Get full text

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition by Burger, Jan A., Landau, Dan A., Taylor-Weiner, Amaro, Bozic, Ivana, Zhang, Huidan, Sarosiek, Kristopher, Wang, Lili, Stewart, Chip, Fan, Jean, Hoellenriegel, Julia, Sivina, Mariela, Dubuc, Adrian M., Fraser, Cameron, Han, Yulong, Li, Shuqiang, Livak, Kenneth J., Zou, Lihua, Wan, Youzhong, Konoplev, Sergej, Sougnez, Carrie, Brown, Jennifer R., Abruzzo, Lynne V., Carter, Scott L., Keating, Michael J., Davids, Matthew S., Wierda, William G., Cibulskis, Kristian, Zenz, Thorsten, Werner, Lillian, Cin, Paola Dal, Kharchencko, Peter, Neuberg, Donna, Kantarjian, Hagop, Lander, Eric, Gabriel, Stacey, O’Brien, Susan, Letai, Anthony, Weitz, David A., Nowak, Martin A., Getz, Gad, Wu, Catherine J.

“…Resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using…”
Get full text

Ventricular arrhythmias and sudden death in patients taking ibrutinib by Lampson, Benjamin L., Yu, Lijian, Glynn, Robert J., Barrientos, Jacqueline C., Jacobsen, Eric D., Banerji, Versha, Jones, Jeffrey A., Walewska, Renata, Savage, Kerry J., Michaud, Gregory F., Moslehi, Javid J., Brown, Jennifer R.

Get full text

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism by Anderson, Mary Ann, Deng, Jing, Seymour, John F., Tam, Constantine, Kim, Su Young, Fein, Joshua, Yu, Lijian, Brown, Jennifer R., Westerman, David, Si, Eric G., Majewski, Ian J., Segal, David, Heitner Enschede, Sari L., Huang, David C.S., Davids, Matthew S., Letai, Anthony, Roberts, Andrew W.

“…BCL2 blunts activation of the mitochondrial pathway to apoptosis, and high-level expression is required for chronic lymphocytic leukemia (CLL) survival…”
Get full text

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials by Brown, Jennifer R, Moslehi, Javid, O'Brien, Susan, Ghia, Paolo, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D, Fraser, Graeme, Rule, Simon, Kipps, Thomas J, Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C, Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F, Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle, Burger, Jan A

“…The first-in-class Bruton's tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been…”
Get full text

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study by O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

“…Summary Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion…”
Get full text

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia? by Brown, Jennifer R

Get full text

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia by Ott, Christopher J., Federation, Alexander J., Schwartz, Logan S., Kasar, Siddha, Klitgaard, Josephine L., Lenci, Romina, Li, Qiyuan, Lawlor, Matthew, Fernandes, Stacey M., Souza, Amanda, Polaski, Donald, Gadi, Deepti, Freedman, Matthew L., Brown, Jennifer R., Bradner, James E.

“…Enhancer profiling is a powerful approach for discovering cis-regulatory elements that define the core transcriptional regulatory circuits of normal and…”
Get full text

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells by Compagno, Mara, Wang, Qi, Pighi, Chiara, Cheong, Taek-Chin, Meng, Fei-Long, Poggio, Teresa, Yeap, Leng-Siew, Karaca, Elif, Blasco, Rafael B., Langellotto, Fernanda, Ambrogio, Chiara, Voena, Claudia, Wiestner, Adrian, Kasar, Siddha N., Brown, Jennifer R., Sun, Jing, Wu, Catherine J., Gostissa, Monica, Alt, Frederick W., Chiarle, Roberto

“…PI3Kδ controls the expression of the recombinogenic enzyme AID; excessive AID activity caused by PI3Kδ inhibition can induce genomic instability in leukaemia…”
Get full text

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease by ROBERTS, Andrew W, SEYMOUR, John F, YUE CUI, BUSMAN, Todd A, MCKEEGAN, Evelyn M, KRIVOSHIK, Andrew P, ENSCHEDE, Sari H, HUMERICKHOUSE, Rod, BROWN, Jennifer R, WIERDA, William G, KIPPS, Thomas J, SEONG LIN KHAW, CARNEY, Dennis A, HE, Simon Z, HUANG, David C. S, HAO XIONG

“…BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related…”
Get full text

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial by Zelenetz, Andrew D, Prof, Barrientos, Jacqueline C, MD, Brown, Jennifer R, MD, Coiffier, Bertrand, Prof, Delgado, Julio, MD, Egyed, Miklós, Prof, Ghia, Paolo, MD, Illés, Árpád, Prof, Jurczak, Wojciech, MD, Marlton, Paula, MBBS, Montillo, Marco, MD, Morschhauser, Franck, Prof, Pristupa, Alexander S, MD, Robak, Tadeusz, Prof, Sharman, Jeff P, MD, Simpson, David, MBChB, Smolej, Lukáš, MD, Tausch, Eugen, MD, Adewoye, Adeboye H, MD, Dreiling, Lyndah K, MD, Kim, Yeonhee, PhD, Stilgenbauer, Stephan, Prof, Hillmen, Peter, Prof

“…Summary Background Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia…”
Get full text

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction by Xu, Lian, Hunter, Zachary R., Yang, Guang, Zhou, Yangsheng, Cao, Yang, Liu, Xia, Morra, Enrica, Trojani, Alessandra, Greco, Antonino, Arcaini, Luca, Varettoni, Marzia, Brown, Jennifer R., Tai, Yu-Tzu, Anderson, Kenneth C., Munshi, Nikhil C., Patterson, Christopher J., Manning, Robert J., Tripsas, Christina K., Lindeman, Neal I., Treon, Steven P.

“…By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in…”
Get full text